“As I said in Marburg, the Pan-African Vaccine Manufacturing Project fits perfectly with Ghana’s roadmap for domestic vaccine development and manufacturing. Ghana is ready to play her role, and I reaffirm, once again, her determination to make the Project work successfully.”
These were the expressions of President Nana Addo Dankwa Akufo-Addo, at the weighty function for the beginning of development of an immunization fabricating plant in Kigali, Rwanda, on Thursday, 23rd June 2022.
Offering his thanks to President Paul Kagame for the challenge to take part in the occasion, President Akufo-Addo demonstrated that the beginning of development “signs to the remainder of the world the initiation of this start to finish antibody fabricating office, including Rwanda, Senegal and my own nation of Ghana.”
In his comments, the President showed that the import of the Pan-African Project implies that Ghana, Senegal and Rwanda should cooperate, the motivation behind why the connection between the Food and Drugs Authorities (FDA) of Ghana and Rwanda is being extended with the marking of another Memorandum of Understanding on Friday, 24th June.
“Through this, FDA Ghana, which achieved WHO Global Benchmarking Maturity Level Three (3) in 2020, and is working hard to achieve Maturity Level Four (4) by the end of this year, will assist FDA Rwanda to attain WHO Maturity Level Three (3) as soon as possible. Both agencies will collaborate further in vaccine drug product manufacturing, fill, finish and lot release in their respective countries,” he said.
President Akufo-Addo continued, “Again, collaboration between our two countries resulted recently in a team from Rwanda visiting research institutions in Ghana, with the aim of strengthening institutional development and partnership towards vaccine discovery and advancement”.
In addition, the President revealed that Ghana’s research institutions are undergoing capacity-building to be ready for the discovery and development of vaccines and other biologicals, stating that “a consortium of Ghanaian pharmaceutical companies, led by DEKS Vaccines Ltd., is working closely with BioNTech Rwanda, BioNTech Germany and kENUP to fill, finish and package the drug product in Ghana from the plant here in Rwanda.”
He thanked BioNTech of Germany, kENUP Foundation, IFC, EIB and the other financial institutions for working closely together with African countries to enable the continent achieve vaccine self-sufficiency.
“I assure all and sundry that Ghana is delighted to be part of this Pan-African Project to manufacture mRNA COVID, Malaria and TB vaccines from drug substance through drug product to fill, finish and package,” the President added.